Plain-English translation of NCT07583784 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a heart attack treated with a stent, patients with atrial fibrillation (irregular heartbeat) typically need to take multiple blood-thinning medications to prevent future clots and strokes. This trial is testing whether a newer type of blood thinner called a DOAC (direct oral anticoagulant) can work safely on its own, without needing to combine it with an additional antiplatelet medication. The goal is to reduce bleeding complications while keeping patients protected from heart attacks and strokes.
Recent studies suggest that using the newer blood thinner alone may provide the same protection as combining it with other medications, while causing fewer serious bleeding problems. This trial wants to confirm whether this simpler treatment approach is truly as safe and effective as the traditional combination approach.
You likely qualify if…
You likely don't qualify if…
After 6 months of your heart attack treatment, you will be assessed to see if you qualify. If you do, you will be randomly assigned to either continue taking the combination of two blood thinners, or to take only the newer blood thinner medication alone. You will take your assigned medications daily and attend follow-up visits where doctors will monitor your health, check for any bleeding problems, and make sure the treatment is working well.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
South Korea